Wegovy

Novo Nordisk selects insider Maziar Mike Doustdar as new CEO, to tackle ‘recent market challenges’
C-Suite

Novo Nordisk selects insider Maziar Mike Doustdar as new CEO, to tackle ‘recent market challenges’

By
July 29, 2025
Ozempic CEO’s exit from Novo started with Teams call surprise
Finance

Ozempic CEO’s exit from Novo started with Teams call surprise

By Naomi Kresge and Bloomberg
May 16, 2025
Zepbound users lost nearly 50% more weight than those on Wegovy in first head-to-head study
Health

Zepbound users lost nearly 50% more weight than those on Wegovy in first head-to-head study

By Jonel Aleccia and The Associated Press
May 12, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health

Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars

By
May 9, 2025
Novo Nordisk slides on pressure from Lilly’s pill study
Retail

Novo Nordisk slides on pressure from Lilly’s pill study

By Marthe Fourcade and Bloomberg
April 22, 2025
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
Finance

Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher

By
March 7, 2025
Interest in GLP-1 medications like Ozempic will continue to grow given the multiple health conditions they can improve.
Commentary

The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up

By
March 4, 2025
Close up of a man's face
Health

50-year-old security guard lost 70 pounds on Wegovy—then gained two pants sizes when he lost insurance coverage

By Tom Murphy and The Associated Press
February 24, 2025
Semaglutide medications Wegovy and Ozempic are pictured
Health

Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers

By Bloomberg, Madison Muller, Ike Swetlitz and Naomi Kresge
February 21, 2025
A woman injects herself with medication.
Health

Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’

By
February 11, 2025
Novo Nordisk President and CEO Lars Fruergaard Jorgensen testifies before the Senate Health, Education, Labor, and Pensions Committee in the Dirksen Senate Office Building on Capitol Hill on September 24, 2024 in Washington, DC. The committee heard testimony from Jorgensen about the price of popular pharmaceuticals made by Novo Nordisk that help treat diabetes and obesity, including Wegovy and Ozempic.
Leadership

As U.S. firms scrap diversity targets, the CEO behind Ozempic and Wegovy took a pay cut for missing them

By
February 5, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health

As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs

By
February 5, 2025
A person stands on a scale.
Health

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

By
February 3, 2025
Ozempic and Wegovy medications side by side
Health

Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity

By The Associated Press, Kenya Hunter and Linley Sanders
January 31, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Health

Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next

By
January 29, 2025

Most Popular